Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Ruxolitinib in malignancy-associated hemophagocytic lymphohistiocytosis (M-HLH): A systematic literature review

View Full Paper
Ask AI
Bookmark
Share

Authors

RPRakesh PatilAKAshwini KhadatkarSRSujay Rainchwar

Discussion

Loading...

Member takes

Overview

Systematic review highlights ruxolitinib's efficacy, achieving complete response in malignancy-related HLH, suggesting a new treatment pathway.

Key Points

  • Ruxolitinib achieved a complete response rate up to 100% in malignancy-associated hemophagocytic lymphohistiocytosis, and shows promise for high-risk cases.
  • Including five studies in the review, the overall response rate reached 89%, with common adverse events being neutropenia and infections.
  • Systematic review conducted under PRISMA guidelines analyzed data pooled from recent trials, focusing on ruxolitinib's role in HLH treatment.
  • The findings suggest ruxolitinib's incorporation may significantly reduce mortality associated with HLH when integrated early with standard therapies.

Cite This Study

Patil et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2b3https://doi.org/10.1182/blood-2025-7213
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis2026
  2. 2Retrospective analysis of ruxolitinib as induction treatment in pediatric hemophagocytic lymphohistiocytosis2025 · 1 citations
  3. 3The clinical features and outcomes of aggressive large B cell lymphoma with concomitant hemophagocytic lymphohistiocytosis at diagnosis2025 · 2 citations
  4. 4Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis2025
  5. 5Ruxolitinib combined with P-gemox in adult patients with newly diagnosed aggressive natural killer cell leukemia2025